These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23179162)

  • 21. Attention-deficit/hyperactivity disorder: increased costs for patients and their families.
    Swensen AR; Birnbaum HG; Secnik K; Marynchenko M; Greenberg P; Claxton A
    J Am Acad Child Adolesc Psychiatry; 2003 Dec; 42(12):1415-23. PubMed ID: 14627876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States.
    Doshi JA; Hodgkins P; Kahle J; Sikirica V; Cangelosi MJ; Setyawan J; Erder MH; Neumann PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Oct; 51(10):990-1002.e2. PubMed ID: 23021476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis.
    Quintero J; Ramos-Quiroga JA; Sebastián JS; Montañés F; Fernández-Jaén A; Martínez-Raga J; Giral MG; Graell M; Mardomingo MJ; Soutullo C; Eiris J; Téllez M; Pamias M; Correas J; Sabaté J; García-Orti L; Alda JA
    BMC Psychiatry; 2018 Feb; 18(1):40. PubMed ID: 29422022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness].
    Schlander M; Trott GE; Schwarz O
    Nervenarzt; 2010 Mar; 81(3):289-300. PubMed ID: 20232510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The health economics of attention deficit hyperactivity disorder in Germany. Part 2: Therapeutic options and their cost-effectiveness].
    Schlander M; Trott GE; Schwarz O
    Nervenarzt; 2010 Mar; 81(3):301-14. PubMed ID: 19936695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
    Lachaine J; Sikirica V; Mathurin K
    BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
    Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Calculation of disease-related costs in claims data analyses with the example of attention-deficit hyperactivity disorder. Comparison of methods].
    Zeidler J; Lange A; Braun S; Linder R; Engel S; Verheyen F; Graf von der Schulenburg JM
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Mar; 56(3):430-8. PubMed ID: 23455561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence.
    Schlander M
    Child Adolesc Psychiatry Ment Health; 2007 Nov; 1(1):13. PubMed ID: 18005403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secular trends and regional variations in pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany.
    Akmatov MK; Holstiege J; Bätzing J
    BMC Psychiatry; 2021 Aug; 21(1):405. PubMed ID: 34391396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
    Molife C; Haynes VS; Nyhuis A; Faries DE; Gelwicks S; Kelsey DK; Alatorre CI
    Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder.
    Secnik K; Swensen A; Lage MJ
    Pharmacoeconomics; 2005; 23(1):93-102. PubMed ID: 15693731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.
    Garbe E; Mikolajczyk RT; Banaschewski T; Petermann U; Petermann F; Kraut AA; Langner I
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):452-8. PubMed ID: 23234588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.
    Erder MH; Signorovitch JE; Setyawan J; Yang H; Parikh K; Betts KA; Xie J; Hodgkins P; Wu EQ
    J Med Econ; 2012; 15(6):1078-87. PubMed ID: 22537226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands.
    Faber A; van Agthoven M; Kalverdijk LJ; Tobi H; de Jong-van den Berg LT; Annemans L; Postma MJ
    CNS Drugs; 2008; 22(2):157-70. PubMed ID: 18193926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
    J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
    Prasad S; Arellano J; Steer C; Libretto SE
    Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second opinions improve ADHD prescribing in a medicaid-insured community population.
    Thompson JN; Varley CK; McClellan J; Hilt R; Lee T; Kwan AC; Lee T; Trupin E
    J Am Acad Child Adolesc Psychiatry; 2009 Jul; 48(7):740-748. PubMed ID: 19465882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costs and treatment patterns of incident ADHD patients - a comparative analysis before and after the initial diagnosis.
    Klora M; Zeidler J; Linder R; Verheyen F; von der Schulenburg JM
    Health Econ Rev; 2015 Dec; 5(1):40. PubMed ID: 26690366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.